Rocket Pharmaceuticals, Inc. (RCKT)
| Market Cap | 394.19M +21.1% |
| Revenue (ttm) | n/a |
| Net Income | -209.38M |
| EPS | -1.88 |
| Shares Out | 109.19M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,322,074 |
| Open | 3.530 |
| Previous Close | 3.540 |
| Day's Range | 3.465 - 3.615 |
| 52-Week Range | 2.530 - 5.450 |
| Beta | 0.47 |
| Analysts | Buy |
| Price Target | 9.39 (+160.11%) |
| Earnings Date | Aug 13, 2026 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing, manufacturing, and selling of genetic therapies for rare and devastating diseases in the United States. It develops in vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 trial; Plakophilin-2 Arrhythmogenic Cardiomyopathy (PKP2-ACM), an inheritable cardia... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for RCKT stock is "Buy." The 12-month stock price target is $9.39, which is an increase of 160.11% from the latest price.
News
Rocket announces safety update from three patients treated with RP-A501
Rocket Pharmaceuticals (RCKT) announced a positive clinical safety update regarding the initial three patients treated under the modified protocol for its global Phase 2 trial of RP-A501 in Danon dise...
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (Rocket or the Company) (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing genetic medicines for rare an...
Rocket Pharmaceuticals closes sale of Rare Pediatric Disease PRV for $180M
Rocket Pharmaceuticals (RCKT) announced the closing of the sale of its Rare Pediatric Disease Priority Review Voucher, PRV, for gross proceeds of $180M. The Rare Pediatric Disease Priority Review Vouc...
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The company has shifted its focus to cardiovascular gene therapies, advancing pivotal trials for Danon and PKP2, and initiating a phase I trial for BAG3. Cash runway extends into Q2 2028, with key regulatory and commercial updates expected this year and next.
Rocket Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
The company is advancing a cardiac-focused genetic medicines pipeline, with pivotal trials for Danon and PKP2 and a new phase I for BAG3. Key regulatory and commercial milestones are expected in the second half of the year, supported by a strong cash position and in-house manufacturing.
Rocket Pharmaceuticals price target raised to $10 from $9 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $10 from $9 and keeps a Buy rating on the shares. The firm came away positive…
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Transcript: AGM 2026
The meeting covered board elections, auditor ratification, executive compensation, and a stock option exchange, with all proposals approved and no questions from shareholders. Voting results will be published in a Form 8-K filing.
Rocket Pharmaceuticals reports Q1 EPS (42c) , consensus (45c)
Cash, cash equivalents and investments as of March 31, 2026, were $144.4 million, excluding PRV monetization. “During the first quarter, we continued advancing our cardiovascular gene therapy portfoli...
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Quarterly report: Q1 2026
Rocket Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 7, 2026.
Rocket Pharmaceuticals Earnings release: Q1 2026
Rocket Pharmaceuticals released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.
Rocket Pharmaceuticals announces $180M sale of priority review voucher
Rocket Pharmaceuticals (RCKT) announced a strengthened financial position following the sale of its Rare Pediatric Disease Priority Review Voucher, PRV. Rocket has entered into a definitive agreement ...
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
CRANBURY, N.J.--(BUSINESS WIRE)--Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, commercial-stage biotechnology company advancing a sustainable pipeline of genetic therapies for rare ...
Rocket Pharmaceuticals Proxy statement: Proxy filing
Rocket Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Rocket Pharmaceuticals Proxy statement: Proxy filing
Rocket Pharmaceuticals filed a proxy statement on April 6, 2026, providing details for shareholder voting and corporate governance matters.
Rocket Pharmaceuticals price target raised to $9 from $8 at BofA
BofA analyst Jason Zemansky raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $9 from $8 and keeps a Buy rating on the shares. Following Kresladi’s approval, the firm…
Rocket Pharmaceuticals price target raised to $11 from $9 at Leerink
Leerink raised the firm’s price target on Rocket Pharmaceuticals (RCKT) to $11 from $9 and keeps a Market Perform rating on the shares after the FDA granted accelerated approval for…
PRV reception could net Rocket $100M-$200M, says LifeSci Capital
LifeSci Capital analyst Patrick Dolezal reiterated an Outperform rating and $9 price target on Rocket Pharmaceuticals (RCKT) after the company announced approval of Kresladi in ultra-rare disease leuk...
Rocket Pharmaceuticals stock weakness unwarranted, says Wedbush
Wedbush reiterated an Outperform rating and $16 price target on Rocket Pharmaceuticals (RCKT), saying the Kresladi approval is a “significant milestone” for the company, which the firm believes reflec...
Rocket Pharmaceuticals Transcript: FDA announcement
FDA granted accelerated approval to KRESLADI, the first gene therapy for severe LAD-I in children. Launch is planned for Q4 2026 with initial treatments at a few specialized centers, and full approval will depend on ongoing patient follow-up and post-marketing data collection.
Rocket Pharmaceuticals Press release: FDA announcement
Rocket Pharmaceuticals issued a press release on March 27, 2026, disclosing material business information to investors.
Rocket Pharma shares climb as FDA approves first therapy for deadly childhood disorder
Rocket Pharmaceuticals shares jumped 10% on Friday before the bell after the U.S. Food and Drug Administration approved its gene therapy for a rare and often fatal immune disorder in children, marki...
Rocket Pharmaceuticals announces FDA approval of Kresladi
Rocket Pharmaceuticals (RCKT) announced that the U.S. Food and Drug Administration, FDA, has granted accelerated approval for Kresladi, an autologous hematopoietic stem cell-based gene therapy indicat...